LRRK2 and Parkinson disease: In the current work, we found those results of acute reversal of mtDNA damage following LRRK2 kinase inhibition to be reproducible in PD patient-derived G2019S LCLs and extended to other models of LRRK2 PD and the selective LRRK2 kinase inhibitor, EB-42618.